Skip to content
INJECTABLE
LARIAGO INJ
LARIAGO INJ
By IPCA
Couldn't load pickup availability
Check Availability
Rapid 3-4 Day Delivery,Tiny Extra Fee!
-
Pet Safe
-
Best Quality
-
Fast Delivery
-
Secure Payment
Collapsible content
About Product
Lariago Injection 30ml, manufactured by Ipca Laboratories Ltd., is a prescription-only, parenteral anti-malarial and anti-amoebic medication formulated to address two critical parasitic health threats: malaria caused by Plasmodium species and extraintestinal amebiasis caused by Entamoeba histolytica. Malaria, transmitted through the bite of infected Anopheles mosquitoes, invades and destroys red blood cells and liver cells, producing potentially life-threatening cycles of fever, organ stress, and systemic collapse. Extraintestinal amebiasis, most commonly presenting as hepatic amoebic abscess, occurs when intestinal parasites breach the gut wall and colonise vital organs. These are serious, rapidly progressing conditions that demand fast-acting, clinically validated pharmacological intervention. Lariago Injection delivers Chloroquine at 40mg/ml in a precise parenteral formulation, allowing rapid systemic absorption and parasiticidal action that oral routes may not reliably provide in critically ill patients. Animeal is proud to offer Lariago Injection 30ml as part of our curated range of prescription veterinary and clinical-grade pharmaceuticals, supporting the welfare of animals and the medical professionals who care for them.
Ingredients:
Chloroquine Phosphate (equivalent to Chloroquine base 40mg per ml): Chloroquine (C18H26ClN3) is a 4-aminoquinoline compound with well-established anti-plasmodial and anti-amoebic pharmacological activity. At the cellular level, Chloroquine accumulates selectively within the acidic food vacuoles of intraerythrocytic Plasmodium parasites. Inside this organelle, the parasite digests haemoglobin as its primary nutrient source, a process that generates toxic ferriprotoporphyrin IX (haem) as a by-product. Under normal parasite physiology, this haem is detoxified by biocrystallisation into inert haemozoin (malaria pigment). Chloroquine intercalates with haem and blocks this biocrystallisation process, causing a rapid and lethal accumulation of free toxic haem within the parasite's vacuole. This triggers oxidative membrane disruption and parasite death. Additionally, Chloroquine raises the intralysosomal pH of parasitised cells, further impairing the proteolytic enzyme activity the parasite depends upon for survival. Its amoebicidal action operates through a similar lysosomal alkalinisation mechanism, disrupting the intracellular environment of Entamoeba histolytica trophozoites, particularly within hepatic tissue where drug concentrations are naturally high after systemic administration. The injectable formulation at 40mg/ml ensures rapid, precise bioavailability, bypassing first-pass hepatic metabolism and guaranteeing therapeutic plasma concentrations within minutes of administration.
Features and Benefits
Rapid Parasiticidal Action Against Plasmodium S...
Rapid Parasiticidal Action Against Plasmodium Species:
Lariago Injection targets the intraerythrocytic stage of Plasmodium parasites with precision, accumulating within the parasite's food vacuole to block haem detoxification and trigger rapid parasite death. Its parenteral delivery ensures therapeutic blood concentrations are achieved rapidly, making it the preferred choice of clinicians in cases where oral intake is compromised by severe vomiting, reduced consciousness, or critical illness.
Effective Against Extraintestinal Amebiasis Including Hepatic Abscess:
Lariago Injection actively reaches the liver at high concentrations following systemic administration, targeting and destroying Entamoeba histolytica trophozoites that have established infection outside the intestinal tract. This makes it a clinically valuable agent in the management of hepatic amoebic abscess, a condition that can progress to life-threatening organ damage if left untreated.
Extended Relapse Prevention in Vivax Malaria:
Beyond the acute treatment phase, Lariago Injection reinforces recovery by extending the relapse-free interval in patients with Plasmodium vivax infection. This is particularly significant given the hypnozoite-mediated relapse pattern of vivax malaria, where residual hepatic parasite stages can reactivate weeks or months after apparent clinical resolution.
Clinically Proven, Globally Recognised Anti-Malarial Efficacy:
With decades of clinical use and regulatory validation, Chloroquine remains one of the most extensively studied anti-malarial agents in medical history. Lariago Injection delivers this proven molecule in a controlled parenteral format, offering consistent, reproducible dosing accuracy under strict professional oversight.
Broad Coverage Across Multiple Plasmodium Species:
Lariago Injection demonstrates activity against Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and susceptible strains of Plasmodium falciparum. This broad-spectrum anti-malarial coverage supports its clinical utility across diverse geographic regions and parasite profiles where Chloroquine-sensitive strains remain prevalent.
Usage and Applications
How to Use:Lariago Injection is a prescription-...
How to Use:
Lariago Injection is a prescription-only medicine and must be administered exclusively by a qualified medical professional or veterinarian in a controlled clinical setting. It must never be self-administered. The dose, frequency, route, and duration of administration will be determined by the attending physician based on the patient's body weight, clinical condition, the severity of infection, and the species of parasite involved. The injection is delivered parenterally, typically via intramuscular or slow intravenous infusion as directed by the prescribing professional. Patients must be monitored throughout the course of treatment for any adverse reactions. All handling, preparation, and disposal of this injectable must comply with standard medical protocols. Do not alter the dose or discontinue treatment without explicit guidance from the treating professional.
Storage Advice:
Store unopened Lariago Injection 30ml in a cool, dry place below 25 degrees Celsius, away from direct sunlight and sources of heat or humidity. Do not freeze. Once opened, the vial must be used immediately under aseptic conditions as directed by the supervising medical professional; do not store a partially used vial for subsequent use unless specifically instructed by a pharmacist or clinician. Keep the product out of reach of children and away from other medications. Do not use after the best-before date printed on the vial label or outer carton.
About the Brand:
Ipca Laboratories Ltd. was founded on 19 October 1949 in Mumbai, India, originally incorporated as The Indian Pharmaceutical Combine Association Limited, and has since grown into a globally recognised integrated pharmaceutical company with manufacturing units certified by the US FDA, UK MHRA, and WHO, exporting to over 120 countries across Asia, Africa, Europe, the Americas, and Australasia. With a portfolio spanning more than 350 formulations and 80 active pharmaceutical ingredients, Ipca applies a rigorous R&D-led approach to pharmaceutical development across therapeutic areas including anti-malarials, cardiovascular, anti-diabetics, and anti-infectives, holding a dominant market position in anti-malarial and DMARD segments in India. The company is committed to backward integration and sustainable manufacturing practices, having invested substantially in renewable energy infrastructure, replacing over 26% of its total power consumption with captive solar and wind energy across its manufacturing sites. This philosophy of quality-driven, responsible pharmaceutical production aligns with Animeal's commitment to offering only clinically credible, professionally validated products for animal and veterinary health. Discover Ipca Laboratories today.
Disclaimer:
Please note that while Lariago Injection 30ml is formulated from Chloroquine Phosphate (40mg/ml) and is used in the treatment of Plasmodium-sensitive malaria and extraintestinal amebiasis, it is a prescription-only injectable pharmaceutical and must never be purchased, stored, or administered without a valid prescription from a registered medical or veterinary professional. This product is not a supplement, nutraceutical, or over-the-counter remedy, and its use outside of a supervised clinical setting poses serious health risks including cardiac arrhythmia, retinal damage, and systemic toxicity. For patients or animals with pre-existing liver disease, kidney disease, cardiac conditions, G-6-PD deficiency, retinal damage, seizure disorders, hearing impairment, or a history of psoriasis or porphyria, consult your veterinarian or physician before introducing this product. Animeal supports your pet's health and happiness journey but does not replace the advice of a qualified veterinary professional.
